NEW YORK (GenomeWeb News) – Agilent Technologies and Seoul National University Hospital in South Korea are collaborating to develop and verify biomarkers for use in developing drugs, they announced Wednesday.

Drugs to be developed as part of the deal include narcotics and immune suppressants.

Agilent is supplying its 6460 Triple Quadrupole LC/MS system, as well as support services and application expertise to the work. The hospital will create and maintain "an optimal environment for new biomarkers to be identified and tested vigorously," the partners said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.